|
产品描述： Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. |
|
靶点：
TrkA;Trkreceptor |
体外研究：
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF |
参考文献：
1. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85. |
|
溶解性：
Soluble in NH4OH、H2O |
|
保存条件：
-20℃ |
配置溶液浓度参考：
|
1mg |
5mg |
10mg |
| 1 mM |
1.723 ml |
8.613 ml |
17.225 ml |
| 5 mM |
0.345 ml |
1.723 ml |
3.445 ml |
| 10 mM |
0.172 ml |
0.861 ml |
1.723 ml |
| 50 mM |
0.034 ml |
0.172 ml |
0.345 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京